Drug Studies Should Be Powered For Safety As Well As Efficacy, FDAer Says
Executive Summary
Drug studies should be powered to assess safety rather than efficacy alone, FDA Office of Pharmacoepidemiology & Statistical Sciences Associate Director for Science, John Senior, MD said at the Pharmaceutical Education Associates Pharmaceutical Risk Management Workshop in Philadelphia Dec. 9
You may also be interested in...
PhRMA/FDA Hepatox Group Wants Research On Liver Monitoring
Actelion's pulmonary hypertension agent Tracleer may provide an opportunity for FDA and industry to test new approaches for management of liver toxicity
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials